Novo Nordisk EVP: "When you're the little brother you're still part of the family. This is important to remember"

EVP Ludovic Helfgott firmly establishes that the Biopharm business is solidly linked with Novo Nordisk's future.

Photo: PR / Novo Nordisk

It doesn't really fit.

The disease area is different, patient groups are significantly smaller, the production of drugs is completely different, and investors typically hate models with more businesses-in-one. Still, this is what it does.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs